Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel‐resistant phenotype
Peter Solár(Beth Israel Deaconess Medical Center), Arthur J. Sytkowski(IQVIA (United States))
Cited by 37
Related Papers
Anticancer Potential of Lichens’ Secondary Metabolites
|Biomolecules|2020|152
Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells
|International Journal of Cancer|2007|59
Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells
|Molecular Cancer Therapeutics|2008|22
Location and the functionality of erythropoietin receptor(s) in A2780 cells
|Oncology Reports|2012|11